xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

521

Orlandi et al.

(Continues)

at 650 mg twice daily and

subsequently decrease to 325 mg twice daily

tissue studies, no clinical benefit after 6 months

primary risk in high

dose desensitization

Significant improvement in symptoms and

medication scores after 3 year long term low dose desensitization

bleeding in low dose desensitization –

decreased by PPI

Desensitization proven effective as the only

specific treatment of choice

significantly reduced,

asthma symptoms in half of patients

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Fruth 1684 2013 2 RCT, placebo controlled Symptom score,

Recommendation to start

Improvement only in

GI side effects GI symptoms are the

Increased risk for GI

CRS symptoms

Clinical improvement Improvement of invitro parameters

medication scores after 1 year

medication score,

recurrence of polyps over 3 years

GI symptoms and bleeding

Improvement for upper and lower airway and invitro

Nasal and pulmonary symptom- and

medication scores during

desensitization

Symptom and

22 Patients with AERD undergoing

desensitization with intranasal lysine aspirin

Baker 1520 2011 2 SR Patients with AERD undergoing high

dose desensitization

Lee 1681 2007 2 RCT 137 AERD patients randomized to different high

maintenance doses

for desensitization

Patients with AERD afterESS

undergoing low dose

desensitization with 100 mg ASA over 3 years

Lanas 1682 2011 2 SR Patients with AERD and low dose desensitization

Pfaar 1672 2006 2 SR Patients with AERD undergoing desensitization

Stevenson 1670 1984 2 DBRCT Patients with AERD undergoing oral desensitization

controlled crossover trial

Parikh 1671 2005 2 Randomized placebo

TABLE X-29 (Continued)